The Global Urinary Incontinence Treatment Devices Market Size was valued at USD 3.39 billion in 2021. It is projected to reach USD 6.02 billion by 2030, growing at a CAGR of 6.58% during the forecast period (2022-2030).
Urinary incontinence is a medical condition that leads to the unintentional loss of urine. Medical devices are used to treat chronic urine incontinence and to develop and strengthen pelvic floor muscles. These devices make possible the practical, safe, and non-invasive treatment of stress, urge, and mixed urine incontinence, which also involves electrical muscle stimulation. They are launching various small, tampon-like disposable items for daily life and flexible silicone rings to stop urine leaks and support the urethra in vaginally prolapsed women.
|Market Size||USD 6.02 billion|
|Fastest Growing Market||Europe|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
A person's quality of life and social and emotional health are significantly impacted by urinary incontinence. Urinary incontinence symptoms can be brought on by various conditions, including urinary tract infections, weakened pelvic floor muscles and urethral sphincters, menopause, pregnancy, childbirth, and post-radical prostatectomy surgery in males. According to a study by Telma Pires et al., published in the July 2020 issue of the journal Human Kinetics, stress urine incontinence affected 20.7% of female athletes worldwide. It was present in 25.9% of female athletes participating in various sports. Volleyball has a rating of 75.6%, making it the sport with the highest prevalence and influence. Female athletes had a high rate of urine incontinence, and high-impact sports may make them more susceptible to stress incontinence.
Urinary incontinence is more common as people age. Several chronic illnesses and environmental variables increase the risk of urine incontinence in elderly persons. Diabetes mellitus, Parkinson's disease, dementia, stroke, prostatic cancer, chronic obstructive pulmonary disease (COPD), and arthritis are chronic conditions linked to urine incontinence. The demand for urinary incontinence treatment devices is expected to rise throughout the projected period due to an increase in the number of people suffering from urine incontinence and a high incidence of urinary incontinence globally due to the aging population.
Synthetic suburethral slings are the most used surgical methods for treating urine incontinence worldwide. Despite having excellent success rates, the procedure's difficulties prevent the industry from expanding. Some of the risks associated with suburethral sling surgery include bleeding, intestinal perforation, urethral or bladder injury, urethral or bladder mesh erosion, vaginal extrusion of mesh, urinary tract infection, pain, urinary urgency, and bladder outlet obstruction, according to a study by Cristiano Mendes Gomes et al. that was published in the International Brazilian Journal of Urology. Additionally, warnings from regulatory bodies about the potential safety risks associated with using mesh for urogynecological reconstruction significantly affected patients, surgeons, and manufacturers globally.
The urethral slings market is predicted to grow since these are strongly indicated for surgical treatment of stress urinary incontinence. Mid-urethral sling surgery is another name for urethral sling procedures. Muscle, ligament, and tendon tissue from the woman or an animal, like a pig, may be utilized to make the sling. It could be made of synthetic materials like absorbable polymers that degrade over time or plastic that is compatible with bodily tissues.
In addition to the low-risk rates and benefits of sling treatments, the segment's rise is also being aided by the rising desire for minimally invasive procedures. Boston Scientific unveiled a revision of the mesh sling system, a surgical device used to treat male patients with stress urinary incontinence. Additionally, the surgical mesh is used to stabilize the urethra neck and treat stress incontinence (SUI). The increasing prevalence of urinary incontinence and ongoing research into the treatment of urinary incontinence are the main drivers of the growth of the urethral slings market.
The global urinary incontinence treatment devices market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant revenue contributor to the global urinary incontinence treatment devices market and is expected to grow at a CAGR of 6.75% during the forecast period. The main drivers of the U.S.'s sizeable market share are the rising number of older persons and the growing demand for minimally invasive surgeries, which contribute to an increase in urinary incontinence. According to the data on global population aging, the number of Americans over the age of 65 is expected to reach 84,813 thousand by 2030, and their population percentage may increase to 22.4% by 2050. Aging caused urine incontinence to become more common, which had a favorable effect on the market. Domestic businesses use product launches, mergers and acquisitions, and research and development methods to improve their market position.
Additionally, the Canadian market is well-established, with both international and domestic businesses. The nation boasts an improved healthcare system that offers top-notch services. Growth potential is expected to be expanded by increased healthcare programs being implemented to raise awareness about urological diseases and the available diagnostics and treatments. For instance, The Canadian Continence Foundation created and manages Incontinence Awareness Month in November each year, encouraging educational and awareness-raising initiatives about incontinence among the general public and professionals across the nation.
Europe is expected to grow at a CAGR of 6.51%, generating USD 1,688.56 million during the forecast period. Due to the rising prevalence of urine incontinence (U.I.), growing healthcare awareness, and growing senior population, Germany has a strong base of international firms focusing on product development. Additionally, increasing rates of neurological conditions like multiple sclerosis (M.S.), which frequently result in urine incontinence, fuel regional market expansion. The urinary incontinence treatment devices market is expanding quickly because the United Kingdom has a robust healthcare system and expanding industrial capabilities. The market is becoming more lucrative due to the increased adoption of cutting-edge technologies in research and development and the presence of major industry players in the nation. Growth potential is expected to be expanded by increased healthcare activities to raise awareness about urological diseases and the diagnostic and available treatment options.
Asia-Pacific is expected to grow significantly during the forecast period. The rising prevalence of urinary incontinence and a solid healthcare system in China are two primary drivers of the market growth for urinary incontinence treatment devices. Additionally, China's healthcare system has a lot of potential because hospitals increasingly use cutting-edge technology. The need for medical technologies is increasing more quickly due to China's healthcare reforms and industrial advancements. According to a literature review titled "Prevalence and Associated Factors of Urinary Incontinence (U.I.) in Women Living in China," between 43 and 349 million Chinese women may be affected by U.I. Several of the identified related factors could be addressed to lower the incidence and prevalence rates of U.I.
The adoption of novel items emerging in the urinary incontinence treatment devices market has increased in India. Additionally, the market analyzed in India is anticipated to develop because of the rising prevalence of urine incontinence (U.I.) and rising healthcare costs. There is a lot of room for improvement in healthcare services, according to the India Brand Equity Foundation (IBEF), given the rising trend in healthcare spending as a share of GDP.
The GCC nations share social and economic backgrounds, health problems, and nearly identical health systems and regulations. South Africa is the most developed nation in Africa, and although it is still developing, it adopts new technologies more quickly. Additionally, increasing public awareness of urological illnesses such as urine incontinence and initiatives by government and nongovernmental groups are anticipated to promote market expansion in the nation. The country with the most sophisticated healthcare systems on the African continent is still South Africa.
Many businesses use the nation as a launching pad to expand into neighboring African nations. Compared to the standards of nations with low and moderate-income populations, Argentina has a well-developed healthcare system. According to the Pan American Health Organization (PAHO), Argentina's healthcare system is incredibly fragmented. This is followed by significant epidemiological transitions, an aging population, and an increasing burden of urological illnesses. Therefore, the high prevalence and incidence of urological disorders in the area and the growing elderly population have contributed to the market growth for urinary incontinence treatment devices.
The global urinary incontinence treatment devices market is segmented by product and end-user.
Based on Product, the global market is bifurcated into urethral slings, electrical stimulation devices, artificial urinary sphincters, catheters and others.
The electrical stimulation devices segment is the highest contributor to the market and is estimated to grow at a CAGR of 6.39% during the forecast period. Electrodes are necessary for electrical stimulation (ES) treatment to deliver electrical current to the body's troubled regions. Patients with urine incontinence may benefit from electrical stimulation therapy, which involves applying electric current to pelvic muscles or lower back nerves involved in urinating. Additionally, pelvic floor muscles (PFM) are strengthened by the use of electrical stimulation devices. A passive, non-invasive method of inducing muscle contraction is electrical stimulation. When treating urine incontinence, it can be used alone or in conjunction with Pelvic Floor Muscle Training (PFMT).
Urinary urge incontinence is also treated with sacral nerve stimulation treatment. In order to stimulate the sacral nerve, a tiny device is connected to the electrode before being implanted in the belly. Additionally, according to clinical trials.gov, Elidah, Inc. began testing the ELITONE-UUI electrical muscle stimulation device's efficacy in treating female urge incontinence. Positive results of these clinical studies with electrical stimulation devices will therefore accelerate the expansion of the entire segment.
For surgical treatment of stress urinary incontinence, urethral slings are strongly advised. The vaginal mesh and colposuspension treatments have been superseded by the urethral sling, regarded as the standard gold technique. Mid-urethral sling surgery is another name for urethral sling procedures. An outpatient treatment, mid-urethral sling surgery typically takes 30 minutes to complete. During this procedure, a sling is wrapped around the urethra to elevate it back into its normal position and provide pressure to the urethra to help with pee retention. The abdominal wall is where the sling is fastened. Muscle, ligament, and tendon tissue from the woman or an animal, like a pig, may be used to make the sling. It might also be made of synthetic materials like absorbable polymers that break down over time or plastic that is compatible with biological tissues. The significant sales of vaginal slings are responsible for the segment's leading market share.
Based on End-User, the global market is bifurcated into hospitals, ambulatory surgical centers, and other end-users.
The hospital segment owns the highest market share and is expected to grow at a CAGR of 6.59% during the forecast period. A hospital, often known as a medical center, offers specialized surgical techniques for patient treatment. Hospitals account for a substantial percentage of the urinary incontinence treatment equipment market since they conduct most surgical procedures. The numerous minimally invasive surgical techniques are used more frequently in hospitals due to the rising number of surgical procedures to cut down on blood loss, infection rates, and operating time.
Most surgical operations, including bariatric, gynecologic, and gall bladder surgeries, are carried out in hospitals due to the simplicity of treating emergency circumstances during surgical procedures or post-operative complications. Additionally, since more technologically advanced technologies are being adopted in developing economies, the expanding number of hospitals throughout developing nations favors the need for urinary incontinence treatment equipment. As a result, hospitals are anticipated to adopt urinary incontinence treatment devices significantly during the projection period.
Ambulatory surgery centers, or ASCs, are cutting-edge medical establishments that provide same-day surgical care, including diagnostic and preventive procedures. Due to the increased prevalence of urological problems, the growing burden of the aging population, and the rising preference for ambulatory services to minimize irrational inpatient costs, ambulatory surgical centers are in greater demand. These factors are the main drivers of market expansion. The preference for ambulatory surgical centers is changing due to the increased need for less invasive treatments, which could further contribute to the high demand for urine incontinence treatment devices in this end-user environment. The demand for ASC to perform various treatments, such as urology and other surgeries, rises due to hospitals' growing load of surgical procedures. Ambulatory surgery centers are standalone buildings designed to perform urological operations at a reasonable price. These institutions are more capable than hospitals and give healthcare providers an additional source of income.